RHEL — Rhelion Life Sciences Cashflow Statement
0.000.00%
Last trade - 00:00- CA$15.35m
- CA$7.90m
- CA$4.20m
Annual cashflow statement for Rhelion Life Sciences, fiscal year end - March 31st, CAD millions except per share, conversion factor applied.
2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | 2026 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -14.7 | -5.8 | -7.71 | -4.31 | -6.84 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 9.7 | 1.49 | 3.61 | 0.94 | 3.82 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.158 | -0.61 | 0.041 | 1.22 | 0.543 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -4.88 | -4.39 | -3.23 | -1.48 | -2.42 |
| Capital Expenditures | -0.407 | -2.06 | -0.694 | -0.531 | -0.14 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -0.176 | -1.11 | 0.043 | 0.006 | -1.09 |
| Acquisition of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.583 | -3.17 | -0.65 | -0.525 | -1.23 |
| Financing Cash Flow Items | 0 | — | -0.089 | 0 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.452 | -0.114 | -0.207 | 0.445 | -0.766 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -5.09 | -7.61 | -4.11 | -1.53 | -4.37 |